CA-GOTRUSTID-INC.
23.3.2021 16:02:07 CET | Business Wire | Press release
Today, GoTrustID Inc. (GoTrust) announced that their Idem Keys have been upgraded from FIDO2 Security Level 1 to Security Level 2 certification for passwordless login for devices, applications and cloud services. The Idem Keys have USB-A, USB-C and NFC interfaces. All GoTrust Idem Keys work with Windows, MAC, Chromebook, iOS and Android phones. The Idem Key can also be used for physical access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005056/en/
An eager customer for the GoTrust Level 2 Idem Key is the mojeID Identity service provided by CZ.NIC. Authorized by the Czech Ministry of the Interior, mojeID is able to access online government services. There are 700,000 users registered with mojeID today.
Going forward, to access more sensitive sites that require the highest level of assurance (LoA) such as opening a bank account or potentially in the future transferring property in property registry, mojeID users will need to use a FIDO2 Security Level 2 token with a security element certified by FIPS/CC. The only such token on the market today that works across every user device is the GoTrust Idem Key. “We were delighted to find exactly the token we required to get LoA High accreditation,” commented Ondřej Filip, CEO at CZ.NIC. “Cooperation with GoTrustID Inc. has been perfect since the beginning and we really admire their decision to go the through L2 certification process.”
Shipment of Idem Keys to CZ.NIC has already started and is expected to grow rapidly as the demand for the highest LoA services increases.
About GoTrustID Inc.
GoTrustID Inc. (GoTrust) is the pioneer company providing a passwordless multi-factor authentication (MFA) platform for an employee’s everyday items: phone, a USB Key or their smart badge. Our mission is to make simple & secure login anywhere and anytime. With every authenticator and server certified by FIDO, GoTrust Authentication Platform makes every employee become their own ID, having effortless login to their computer, corporate systems and cloud services. GoTrustID has twenty-four international patents granted, including six US patents.
GoTrust FIDO2 Security Level 2 Idem Key is available on Amazon. https://www.amazon.com/dp/B07YTL3Q1Y?ref=myi_title_dp
About CZ.NIC
CZ.NIC, z. s. p. o., is an interest association of legal entities, founded in 1998. The association currently has 117 members. One key activity of the association is the operation of the domain name registry for the .CZ domain. The association is now intensively working on development of the mojeID service supporting new technologies and projects beneficial to the Internet infrastructure in the Czech Republic.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005056/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom